Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. | Zendy

A. Overlack | Zendy; K. O. Stumpe | Zendy; R. Kolloch | Zendy; C. Ressel | Zendy; F Krueck | Zendy

Open Access

Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study.

Author(s) -

A. Overlack,

K. O. Stumpe,

R. Kolloch,

C. Ressel,

F Krueck

Publication year - 1981

Publication title -

hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.986

H-Index - 265

eISSN - 1524-4563

pISSN - 0194-911X

DOI - 10.1161/01.hyp.3.3_pt_2.i18

Subject(s) - kallikrein , endocrinology , medicine , supine position , essential hypertension , blood pressure , placebo , excretion , chemistry , biochemistry , enzyme , pathology , alternative medicine

The antihypertensive effect of oral administration of pig pancreatic kallikrein was investigated in a double blind study of 20 patients with essential hypertension. Kallikrein treatment lowered the blood pressure (BP) significantly from 159.5/104.5 to 146.3/92.8 mm Hg in the supine and from 153/106.1 to 136.1/95.6 mm Hg in the standing position. Blood pressure remained unchanged in the placebo group. Urinary kallikrein, sodium excretion, and GFR increased with treatment, but these changes did not reach statistical significance, In the kallikrein-treated patients but not in the placebo group, urinary kallikrein was correlated both to GFR (r = 0.7, p less than 0.001) and sodium excretion (r = 0.5, p less than 0.01). The antihypertensive mechanism of kallikrein treatment remains unknown. It could be speculated that kallikrein may induce changes in local blood flow, mediated by kinin and prostaglandin release.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research